Clinical Trial Update: Dexpramipexole Dose-Ranging Biomarker Study in Subjects With Eosinophilic Asthma [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging biomarker study of dexpramipexole in eosinophilic asthma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Eosinophilic Asthma

Drugs mentioned

• Dexpramipexole (dexpramipexole)

Snippet

Sponsor: Knopp Biosciences | Conditions: Eosinophilic Asthma, Asthma | Phase 2 | Status: COMPLETED | Results posted: 2021-12-22